(Q51996142)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Brian Druker

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Richard D Press

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Sherbenou DW

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Wong MJ

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Humayun A

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

McGreevey LS

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Harrell P

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Yang R

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Mauro M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Deininger MW

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

25 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

489-493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404554

24 December 2019

exact match

0 references

cites work

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Dynamics of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404554

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404554

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252009%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference